- Joined
- Dec 15, 2005
- Messages
- 15,391
- Reaction score
- 21,603
In Oct of 2013, the American Journal of OB & Gyn published an article "Evidence-based surgery for cesarean delivery: an updated systematic review" in which they stated, among other things
Recommendation B =
TXA is cheap, appears to be safe. We used gallons of it for trauma patients in Afghanistan without thrombotic complications. Pregnancy's a different thrombosis risk than trauma but the c-section studies they reference seem to support safety.
So, what are you all doing? Is TXA hanging next to the cefazolin prior to every c-section you do? Should it?
I haven't read the articles this one references, but my initial thought is that a statistically significant difference in blood loss makes for a publishable article, but whether or not that difference in blood loss is clinically significant is another issue. Less need for a 2nd utertonic? So what? I suspect that if there was a difference in actual morbidity, ie emergency hysterectomy rate, or transfusion rate, they'd have mentioned that.
Tranexamic acid (10 mg/kg intravenously prior to incision) is an antifibrinolytic and hemostatic agent, and 3 new RCTs have evaluated its use in decreasing blood loss in CD.48,56,57 In these trials, tranexamic acid significantly decreased intraoperative and postpartum blood loss (100-200 mL). In one trial, the EBL of greater than 1000 mL and the need for additional uterotonics was significantly lower in the tranexamic acid group (2.1% vs 5.8%; RR, 2.7; 95% CI, 1.1e6.3; and 8.5% vs 14.5%; RR, 1.7; 95% CI, 1.1e2.6, respectively)48 (recommendation: B; level of certainty: moderate; Table 1; new).
Recommendation B =
And "moderate" level of certainty =The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as:
- The number, size, or quality of individual studies.
- Inconsistency of findings across individual studies.
- Limited generalizability of findings to routine primary care practice.
- Lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
TXA is cheap, appears to be safe. We used gallons of it for trauma patients in Afghanistan without thrombotic complications. Pregnancy's a different thrombosis risk than trauma but the c-section studies they reference seem to support safety.
So, what are you all doing? Is TXA hanging next to the cefazolin prior to every c-section you do? Should it?
I haven't read the articles this one references, but my initial thought is that a statistically significant difference in blood loss makes for a publishable article, but whether or not that difference in blood loss is clinically significant is another issue. Less need for a 2nd utertonic? So what? I suspect that if there was a difference in actual morbidity, ie emergency hysterectomy rate, or transfusion rate, they'd have mentioned that.